XDR SHIGELLA US EMERGENCE — CDC MMWR APRIL 2026
Title: "Emergence of Extensively Drug-Resistant
Currently interpreted as supporting evidence for 13 tracked assessments.
Public note
For situational awareness and research transparency. Not medical advice.
System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.
Moderate confidence
The evidence is meaningful, but there is still material uncertainty. Based on 1 linked evidence item and assessed against Dec 31, 2026.
02
The criteria the system uses to determine whether this assessment is borne out by the stated horizon.
Method
The condition the system checks for when evaluating this assessment.
Minimum source quality
Evidence must meet or exceed this credibility tier to count toward evaluation.
Required terms
fluoroquinolonessimultaneouslyazithromycinsurveillance03
Tracking since Apr 20, 2026.
06
The current analyst narrative for this scope.
AMR evidence pipeline severely constrained this cycle; two hypotheses resolve Apr 27 without confirmatory data; PubMed failure and stale secondary connectors limit incident coverage.
Resolves Apr 27; no PulseNet data; likely no-resolve
07
1 linked item.
Currently interpreted as supporting evidence for 13 tracked assessments.
Integrity anchor
Brier 0.202
19 resolved novel pathogen detection predictions.